OCA at 05:54, 23 August 2023

OCA — Wed, 23 Aug 2023 05:54:28 GMT

←Older revision		Revision as of 05:54, 23 August 2023
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 8hy7 is ~~ON HOLD~~	+	==EGFR kinase domain mutant "TMLR" with compound 28f==
-		+	<StructureSection load='8hy7' size='340' side='right'caption='[[8hy7]], [[Resolution\|resolution]] 2.91Å' scene=''>
-	~~Authors~~: ~~Wang~~, Y.X., Wu, C.Y.	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[8hy7]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8HY7 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8HY7 FirstGlance]. <br>
-	~~Description~~: EGFR kinase ~~domain mutant ""TMLR""~~ with ~~compound 28f~~	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.91Å</td></tr>
-	[[Category: ~~Unreleased~~ Structures]]	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NSO:~{N}-[3-[[6-fluoranyl-2-[[4-(4-methylpiperazin-1-yl)phenyl]amino]quinazolin-4-yl]amino]phenyl]prop-2-enamide'>NSO</scene></td></tr>
-	[[Category: Wang~~, Y.X~~]]	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8hy7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8hy7 OCA], [https://pdbe.org/8hy7 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8hy7 RCSB], [https://www.ebi.ac.uk/pdbsum/8hy7 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8hy7 ProSAT]</span></td></tr>
-	[[Category: Wu~~, C.Y~~]]	+	</table>
		+	== Disease ==
		+	[https://www.uniprot.org/uniprot/EGFR_HUMAN EGFR_HUMAN] Defects in EGFR are associated with lung cancer (LNCR) [MIM:[https://omim.org/entry/211980 211980]. LNCR is a common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.
		+	== Function ==
		+	[https://www.uniprot.org/uniprot/EGFR_HUMAN EGFR_HUMAN] Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin.<ref>PMID:7657591</ref> <ref>PMID:11602604</ref> <ref>PMID:12873986</ref> <ref>PMID:10805725</ref> <ref>PMID:11116146</ref> <ref>PMID:11483589</ref> <ref>PMID:17115032</ref> <ref>PMID:21258366</ref> <ref>PMID:12297050</ref> <ref>PMID:12620237</ref> <ref>PMID:15374980</ref> <ref>PMID:19560417</ref> <ref>PMID:20837704</ref> Isoform 2 may act as an antagonist of EGF action.<ref>PMID:7657591</ref> <ref>PMID:11602604</ref> <ref>PMID:12873986</ref> <ref>PMID:10805725</ref> <ref>PMID:11116146</ref> <ref>PMID:11483589</ref> <ref>PMID:17115032</ref> <ref>PMID:21258366</ref> <ref>PMID:12297050</ref> <ref>PMID:12620237</ref> <ref>PMID:15374980</ref> <ref>PMID:19560417</ref> <ref>PMID:20837704</ref>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Homo sapiens]]
		+	[[Category: Large Structures]]
		+	[[Category: Wang YX]]
		+	[[Category: Wu CY]]

OCA: Protected "8hy7" [edit=sysop:move=sysop]

OCA — Wed, 11 Jan 2023 06:21:22 GMT

Protected "8hy7" [edit=sysop:move=sysop]

←Older revision

Revision as of 06:21, 11 January 2023

OCA: New page: '''Unreleased structure''' The entry 8hy7 is ON HOLD Authors: Wang, Y.X., Wu, C.Y. Description: EGFR kinase domain mutant ""TMLR"" with compound 28f Category: Unreleased Structures...

OCA — Wed, 11 Jan 2023 06:21:21 GMT

New page: '''Unreleased structure''' The entry 8hy7 is ON HOLD Authors: Wang, Y.X., Wu, C.Y. Description: EGFR kinase domain mutant ""TMLR"" with compound 28f Category: Unreleased Structures...

New page

'''Unreleased structure'''

The entry 8hy7 is ON HOLD

Authors: Wang, Y.X., Wu, C.Y.

Description: EGFR kinase domain mutant ""TMLR"" with compound 28f
[[Category: Unreleased Structures]]
[[Category: Wang, Y.X]]
[[Category: Wu, C.Y]]

8hy7 - Revision history

OCA at 05:54, 23 August 2023

OCA: Protected "8hy7" [edit=sysop:move=sysop]

OCA: New page: '''Unreleased structure''' The entry 8hy7 is ON HOLD Authors: Wang, Y.X., Wu, C.Y. Description: EGFR kinase domain mutant ""TMLR"" with compound 28f Category: Unreleased Structures...